Results 1 to 10 of about 204,163 (273)

Febrile neutropenia [PDF]

open access: yesJournal of Pediatric Critical Care
Infections occur frequently in oncological and transplant settings and are complicated due to several factors not limited to the degree of immunosuppression, healthcare exposure, and antimicrobial resistance.
Vidya Krishna, Jui Athavale-Wad
doaj   +9 more sources

A multicenter prospective study of 515 febrile neutropenia episodes in Argentina during a 5-year period.

open access: yesPLoS ONE, 2019
For better management of patients with febrile neutropenia, our study investigated the epidemiologic, microbiologic, and clinical characteristics of adult inpatients with febrile neutropenia and their mortality-associated factors. To this end, we carried
Roberto L Parodi   +9 more
doaj   +2 more sources

Epidemiology and source of infection in patients with febrile neutropenia: A ten-year longitudinal study

open access: yesJournal of Infection and Public Health, 2019
Objectives: No recent studies are available from Saudi Arabia on the etiology of febrile neutropenia. The objective of this study was to describe the characteristics of patients with febrile neutropenia and to calculate the rate of occurrence of ...
Jaffar A. Al-Tawfiq   +7 more
doaj   +2 more sources

Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil

open access: yesWorld Journal of Surgical Oncology, 2019
Background The docetaxel, 5-fluorouracil, and cisplatin (DCF) regimen is an effective form of chemotherapy for advanced esophageal cancer. However, the incidence of adverse events such as febrile neutropenia and hematological toxicity is high.
Yu Ohkura, Masaki Ueno, Harushi Udagawa
doaj   +2 more sources

Prescribing Empiric Antibiotics for Febrile Neutropenia: Compliance with Institutional Febrile Neutropenia Guidelines

open access: yesPharmacy, 2018
Background: Febrile neutropenia (FN) is an oncologic emergency which should be treated immediately with empiric antibiotics. Different institutions observe different antibiograms and use different FN management guidelines.
Doaa Naeem   +3 more
doaj   +2 more sources

Empiric Imipenem/Cilastatin/Relebactam for Febrile Neutropenia After Allogeneic Hematopoietic Stem Cell Transplantation: Two Case Reports [PDF]

open access: yesJournal of Blood Medicine
Dao-Xing Deng,* Ting Wang,* Hui Sun,* Jun Kong, Yuan-Yuan Zhang, Le-Qing Cao, Xiao-Dong Mo Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center
Deng DX   +6 more
doaj   +2 more sources

Comprehensive evaluation of risk factors for the development and complications of chemotherapy-induced febrile neutropenia [PDF]

open access: yesSrpski Arhiv za Celokupno Lekarstvo, 2022
Febrile neutropenia is a serious adverse effect of chemotherapy. It can lead to complications and death, as well as delays in treatment, chemotherapy dose reductions, compromised treatment efficacy, and reduced survival.
Dimitrijević Jelena   +3 more
doaj   +1 more source

Prophylaxis and management of chemotherapy-induced febrile neutropenia: The role of myeloid growth factors [PDF]

open access: yesMedicinski Podmladak, 2022
Febrile neutropenia is a serious chemotherapy-related adverse event that can lead to complications and death and it could be a significant burden on the organization of the health care system.
Dimitrijević Jelena, Stojanović Marko
doaj   +1 more source

Febrile neutropenia in the emergency department

open access: yesCurrent Medical Issues, 2021
Introduction: Febrile neutropenia is one of the most common presentations to the emergency department. Identification and empirical antibiotic therapy improve the outcome of these patients.
Malle Simeon   +2 more
doaj   +1 more source

Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma

open access: yesBone Marrow Transplantation, 2022
Chimeric Antigen Receptor T cells (CAR-T) are an outbreaking treatment option for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are the ...
R. Lievin   +14 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy